[Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma]. / Biomarqueurs tissulaires des immunothérapies anti-PD-1 dans le mélanome.
Ann Pathol
; 37(1): 55-60, 2017 Feb.
Article
em Fr
| MEDLINE
| ID: mdl-28111041
ABSTRACT
Prognosis and treatment of advanced melanoma have been transformed by the success of immunotherapies, in particular agents targeting PD-1. PD-L1 expression assessed by immunohistochemistry in not an effective predictive biomarker to select patients in this tumor type, since significant clinical benefit was observed in the group of patients with negative tumors. The predictive value of PD-L1 testing to select patients for combination of anti-PD-1 and anti-CTLA-4 agents is under evaluation. Other tissue biomarkers are emerging to identify sensitive tumors to anti-PD-1 agents. In particular, assessment of immune infiltrates in tumor tissue, mutational load and tumor neoantigens seem promising in melanoma.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores
/
Terapia de Alvo Molecular
/
Anticorpos Monoclonais Humanizados
/
Antígeno B7-H1
/
Receptor de Morte Celular Programada 1
/
Antineoplásicos Imunológicos
/
Imunoterapia
/
Melanoma
/
Anticorpos Monoclonais
/
Proteínas de Neoplasias
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
Fr
Revista:
Ann Pathol
Ano de publicação:
2017
Tipo de documento:
Article